Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Forgot password?
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Quick Order
Products
Antibodies
ELISA and Assay Kits
Research Areas
Infectious Disease
Resources
Purchasing
Reference Material
Contact Us
Location
Corporate Headquarters
Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States
Telephone Numbers
Customer Service: (800) 227-6666 / (650) 697-3600
Contact Us
Additional Contact Details
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Forgot password?
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Quick Order
KDR / VEGFR2 / FLK1
kinase insert domain receptor (a type III receptor tyrosine kinase)
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
| Gene Name: | kinase insert domain receptor (a type III receptor tyrosine kinase) |
| Family/Subfamily: | Protein Kinase , VEGF Receptor |
| Synonyms: | KDR, CD309, Fetal liver kinase 1, Fetal liver kinase-1, FLK-1, FLK1, Kinase insert domain receptor, Quek1, VEGFR, VEGFR2, Soluble VEGFR2, VEGF receptor 2, VEGFR-2, CD309 antigen, VEGF-R2 |
| Target Sequences: | NM_002253 NP_002244.1 P35968 |
Publications (11)
1
Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. Rahimi N, Dayanir V, Lashkari K. The Journal of biological chemistry. 2000 275:16986-92. (WB, IP)
[PubMed:10747927]
2
Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. The American journal of pathology. 2000 156:1337-44. (IHC-P; Human)
[PubMed:10751359]
[PMC:PMC1876877]
3
The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling. Meyer RD, Singh AJ, Rahimi N. The Journal of biological chemistry. 2004 279:735-42. (WB, IP)
[PubMed:14573614]
[PMC:PMC1464116]
☰ Filters
Products
Proteins
(34)
Type
Over-Expression Lysate
(2)
Recombinant
(32)
Target
KDR / VEGFR2 / FLK1
(34)
Application
Bind
(3)
ELISA
(1)
Func
(1)
SDS-PAGE
(9)
Publications
No
(34)
Tag
AVI-6His, C-terminus
(1)
DDK,C-terminus
(2)
Fc
(3)
Fc, C-terminus
(3)
GST
(1)
GST, N-terminus
(1)
His
(5)
His, N-Terminal
(1)
His,C-terminus
(5)
His-GST
(2)
His-GST, N-terminus
(1)
His-S
(1)
Human IgG Fc, C-terminus
(4)
Myc-DDK (Flag)
(2)
Species
Human
(22)
Mouse
(7)
Pig
(1)
Rat
(3)
Source
293F Cells
(1)
293T Cells
(1)
Baculovirus
(2)
CHO Cells
(1)
E. coli
(5)
HEK 293 Cells
(10)
Human
(2)
Human Cells
(7)
Mammalian Cells
(2)
Sf9 Cells
(2)
Wheat Germ Extract
(1)
Purification
Purified
(6)
Low Endotoxin Level
Low endotoxin level
(23)
Biologically Active
Biologically active
(8)
HEK 293 Cells
Human IgG Fc, C-terminus
Bind ELISA Func SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human VEGFR2/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 979 amino acids and predicts a molecular mass of 109 kDa. The apparent molecular mass of rh VEGFR2/Fc monomer is approximatly 150-160 in SDS-PAGE under reducing conditions.
100 µg/$480; 1 mg/$2,324
E. coli
His
32.7 kDa
10 µg/$268; 50 µg/$362; 100 µg/$577; 200 µg/$722; 1 mg/$1,755; 500 µg/$1,325; 5 mg/$2,708; 2 mg/$1,934
E. coli
His-S
36.8 kDa
10 µg/$263; 50 µg/$343; 200 µg/$662; 100 µg/$530; 1 mg/$1,657; 500 µg/$1,242; 5 mg/$2,600; 2 mg/$1,832
Human Cells
Fc, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
110.4kD
10 µg/$277; 50 µg/$395; 500 µg/$1,203; 1 mg/$1,627
HEK 293 Cells
Human IgG Fc, C-terminus
Bind SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant mouse KDR /Fc comprises 984 amino acids and has a predicted molecular mass of 110 kDa. The apparent molecular mass of the protein is approximately 120 kDa in SDS-PAGE under reducing conditions due to glycosylation.
100 µg/$441; 1 mg/$2,003
Human KDR / VEGFR2 / FLK1 Protein (Recombinant Human IgG Fc, C-terminus) (Asp120-Lys327) - LS-G47191
HEK 293 Cells
Human IgG Fc, C-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 449 amino acids and predicts a molecular mass of 50.4 kDa.
200 µg/$633
HEK 293 Cells
Human IgG Fc, C-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 549 amino acids and predicts a molecular mass of 61.5 kDa.
200 µg/$633
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 319 amino acids and predicts a molecular mass of 35.9 kDa.
200 µg/$633
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR consists of 219 amino acids and predicts a molecular mass of 24.8 kDa.
200 µg/$633
HEK 293 Cells
His,C-terminus
Bind SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The secreted recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of rhVEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions.
100 µg/$480; 1 mg/$2,324
Baculovirus
His-GST, N-terminus
SDS-PAGE
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant human KDR /GST chimera consists of 787 amino acids and has a calculated molecular mass of 89.3 kDa. The recombinant protein migrates as an approximately 110 kDa band in SDS-PAGE under reducing conditions.
50 µg/$410; 500 µg/$1,735
HEK 293 Cells
His,C-terminus
SDS-PAGE
Less than 1.0 EU/µg protein (determined by LAL method).
The recombinant mouse KDR consists of 754 amino acids and predicts a molecular mass of 84.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rmKDR is approximately 100-110 kDa as a result of glycosylation.
100 µg/$441; 1 mg/$2,003
Wheat Germ Extract
GST, N-terminus
10 µg/$479; 25 µg/$670
Baculovirus
His-GST
Less than 1.0 EU/µg protein (determined by LAL method).
89.3 kDa
50 µg/$707
Human Cells
Fc
Less than 1.0 EU/µg protein (determined by LAL method).
110 kDa
100 µg/$721
HEK 293 Cells
Myc-DDK (Flag)
152 kDa
100 µg/$710
293T Cells
Myc-DDK (Flag)
152 kDa
20 µg/$215
Human
AVI-6His, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
86.1 kDa
20 µg/$416; 100 µg/$910
Human
Fc, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
110 kDa
10 µg/$273; 50 µg/$398
HEK 293 Cells
None
Biologically active
Less than 0.01 ng/µg (determined by LAL method).
The 976 amino acid recombinant protein has a predicted molecular mass of approximately 109 kD. The DTT-reduced and non-reduced glycosylated protein migrate at approximately 200 kD and >250 kD respectively by SDS-PAGE. The N-terminal amino acid is Ala.
10 µg/$291; 25 µg/$344; 100 µg/$620
CHO Cells
None
Biologically active
Less than 0.01 ng/µg (determined by LAL method).
The 983 amino acid recombinant protein has a predicted molecular mass of approximately 110 kD. The DTT-reduced and non-reduced glycosylated proteins migrate at approximately 200 kD and >250 kD, respectively, by SDS-PAGE. The N-terminal amino acid is Ala.
10 µg/$291; 25 µg/$344; 100 µg/$620
Mammalian Cells
Fc, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
110.4 kDa
10 µg/$277; 50 µg/$389
Mammalian Cells
His,C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
84.3 kDa
10 µg/$317; 50 µg/$524
Sf9 Cells
DDK,C-terminus
37.2 kDa
20 µg/$677
Sf9 Cells
DDK,C-terminus
83.3 kDa
20 µg/$677
Viewing 1-25
of 34
product results
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.
